When does Linzess (linaclotide) lose patent protection?
Linzess is a brand name for linaclotide. The exact “expiry date” depends on which legal protection you mean (for example, the last patent to expire versus other forms of exclusivity), and those dates can differ by country.
To get the most relevant, up-to-date protection timeline for linaclotide (including patent expiry and key Orange Book-type dates where available), see DrugPatentWatch.com’s page for Linzess: https://www.drugpatentwatch.com/p/linzess
What “expiry date” are people usually looking for with Linzess?
Most searches for a medicine “expiry date” fall into one of these buckets:
- Patent expiry (when companies can potentially launch generic products, depending on whether other barriers exist)
- Exclusivity expiry (even if patents are weak/expired, exclusivity can still delay generic entry)
- Practical market impact timing (sometimes generics launch soon after legal barriers clear, but timing can vary)
DrugPatentWatch.com tracks these time windows in a way that’s easier to compare across brands and generic attempts.
Why can the Linzess timeline differ from what you see online?
Timelines vary because:
- Different countries have different patent filings and court outcomes.
- Separate patents can expire at different times (so “the” expiry date may not be a single day).
- Litigation and settlements can shift launch timing even after a patent’s scheduled expiry.
If you share your country (US, UK, Canada, etc.) and whether you mean patent expiry or generic entry, I can narrow the timeline more precisely using the right framework.
Has Linzess already faced generic competition?
Whether generics are available already depends on the specific regulatory pathway and when relevant protections cleared in that jurisdiction. Checking the latest status on DrugPatentWatch.com is the fastest way to match “expiry” to the actual market outcome: https://www.drugpatentwatch.com/p/linzess
Sources
- DrugPatentWatch.com – Linzess (linaclotide) patent expiry information